Search
Displaying 461–470 of 866 results for “vision connection”
-
South Carolina Sight Committee
The South Carolina Sight Committee provides a platform for professionals serving the blind and low vision community in South Carolina and surrounding areas to showcase services and other resources.
-
Foundation Fighting Blindness Announces Over $9 Million in New Research Awards for FY2025
Research NewsThe Foundation Fighting Blindness is proud to announce the funding of 16 innovative research projects in Fiscal Year 2025, totaling over $9 million in new grants.
-
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
Research NewsNACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
Invisible Disability
You cannot tell by looking at me that I am visually impaired. The #1 reaction to my lack of sight confession, though, hands down, is a nervous laugh followed by the person not believing me.
-
Eye on the Cure Podcast | Episode 89: Dr. Christine Curcio
Eye on the CureDr. Curcio talks to host Ben about her epic career and recent Proctor Medal lecture with Dr. Cynthia Owsley at the 2025 ARVO conference.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Research NewsThe company plans to complete BLA submission in early 2026.
-
The Charlotte Consortium provides a platform for professionals serving the blind and low vision community in Charlotte, NC, and surrounding areas to showcase services and other resources.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
The Reality of an Invisible Disability: A Storytelling Series
“The Reality of an Invisible Disability,” a new storytelling content series dedicated to amplifying the voices of individuals experiencing vision loss, at any spectrum. This series aims to shed light on the invisible experience that unifies all disabilities, providing a platform for sharing personal and raw experiences, and fostering a community of understanding and advocacy.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
